From the 1Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh School of Medicine and the Magee-Womens Research Institute; 2Section of Decision Sciences and Clinical Systems Modeling, Department of Medicine, University of Pittsburgh School of Medicine; and 3Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania.
Funded by an anonymous foundation.
The authors thank Eleanor B. Schwarz, MD, MS, for her editorial advice and assistance in the preparation of this manuscript.
Presented in part at the First Annual Meeting of the Society of Family Planning, September 8–10, 2005, St. Petersburg, Florida; and at the 27th Annual Meeting of the Society of Medical Decision Making, October 21–24, 2005, San Francisco, California.
Corresponding author: Matthew F. Reeves, MD, MPH, Department of Obstetrics, Gynecology, and Reproductive Sciences, Magee-Womens Hospital, 300 Halket Street, Pittsburgh, PA 15213-3180; e-mail: [email protected].
Financial Disclosure Dr. Creinin is a consultant for and receives honoraria and research support from Berlex, the supplier of Mirena in the United States.
